Alisertib and hormone therapy for advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new drug, alisertib, combined with hormone therapy for people with HR-positive, HER2-negative breast cancer that has spread or come back and is no longer curable. It may be an option if you've already tried at least two hormone therapies and a CDK4/6 inhibitor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your breast cancer must be HR-positive and HER2-negative.
- Your cancer must have spread or come back and cannot be cured with standard treatments.
- You must have tried at least two different hormone therapies for advanced or metastatic disease.
- You must have taken a CDK4/6 inhibitor together with hormone therapy.
- You cannot have had chemotherapy for advanced or metastatic breast cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental pill that targets a protein called Aurora A kinase, which may help overcome resistance to standard treatments. The goal is to see if adding this pill to your usual hormone and HER2 therapy can slow down or stop the growth of your cancer.
This trial tests a new combination of two targeted medicines for people with a certain type of advanced breast cancer that has grown despite hormone therapy. The medicines may help shrink tumors and slow the cancer's growth.
This trial tests a combination of a new immunotherapy drug (adebrelimab) with a targeted pill (dalpiciclib) and standard hormone therapy for women with advanced hormone receptor positive, HER2 negative breast cancer. It may help patients who have not yet had certain prior treatments, aiming to slow the cancer's growth.
This trial tests two new drugs (sapanisertib and serabelisib) alone or together to treat advanced breast cancer that is hormone-receptor positive. These drugs target specific pathways that help cancer grow, and the trial will see if they work better than standard treatments.
This trial tests a combination treatment including anlotinib for women with hormone receptor-positive breast cancer that has spread to other parts of the body and has stopped responding to standard therapies. It is for those who have already tried a CDK4/6 inhibitor and endocrine therapy.
This trial tests combining elacestrant (a new hormone therapy) with exemestane (a standard hormone therapy) for people whose HR+/HER2- breast cancer has spread and who have already tried a CDK4/6 inhibitor with anastrozole or letrozole. It may help if your tumor shows certain activity on a special PET scan.
Hear when a new Hormone Receptor Positive HER-2 Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.